Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917855 | 1.00 | DPP4 (0.48) | DPP4DPP8MMP2ADAMTS5BTK | |
| SCHEMBL8221580 | 0.86 | DPP4 (0.43) | DPP4DPP8BTKVNN1JAK3 | |
| SCHEMBL3920732 | 0.84 | DPP4 (0.48) | DPP4DPP8BTKSMN1; SMN2 | |
| SCHEMBL3920725 | 0.84 | DPP4 (0.48) | DPP4DPP8BTKSMN1; SMN2 | |
| SCHEMBL21434133 | 0.75 | CHRM4 (0.39) | BTK | |
| SCHEMBL8217907 | 0.74 | DPP4 (0.43) | DPP4DPP8BTKVNN1JAK3 | |
| SCHEMBL23492799 | 0.71 | PSEN1 (0.42) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23492798 | 0.71 | PSEN1 (0.42) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23492797 | 0.71 | PSEN1 (0.42) | BTKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5924085 | 0.71 | DPP4 (0.48) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | DPP4 783/4885DPP8 1978/4885MMP2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.